Smart Drug Delivery Systems for Precision Medicine

Stephen Vure Mustapha [1*], Ashiata Yetunde Tomoh [2], Busayo Gbaraba [3]

[1] Independent Researcher, Greater Manchester, UK

[2] Kwara State Ministry of Health, Nigeria

[3] Kaybat Pharmacy & Stores, Benin, Nigeria

* Corresponding Author: **Stephen Vure Mustapha**

Article Info

Abstract

The convergence of nanotechnology and precision medicine has catalyzed the development of sophisticated smart drug delivery systems (SDDS) capable of delivering therapeutic agents with unprecedented specificity and spatiotemporal control. Unlike conventional drug delivery approaches, SDDS exploit disease-specific microenvironmental cues—including aberrant pH gradients, elevated glutathione levels, overexpressed enzymes, and hypoxic conditions—alongside externally applied stimuli such as light, temperature, and magnetic fields, to achieve on-demand payload release at the target site. This review aims to provide a comprehensive and critical appraisal of the current landscape of smart nanocarrier-based delivery platforms, including polymeric nanoparticles, liposomes, solid lipid nanoparticles, mesoporous silica nanoparticles, dendrimers, and emerging bio-inspired exosome-based carriers. Key stimuli-responsive and ligand-mediated targeting strategies are examined in the context of their mechanistic underpinnings and translational relevance. Major therapeutic applications discussed encompass targeted oncology, antimicrobial therapy for drug-resistant infections, management of chronic metabolic disorders, and genomic medicine encompassing siRNA and CRISPR-based therapeutics. Despite remarkable progress, challenges surrounding clinical translation—including manufacturing scalability, *in vivo* stability, immunogenicity, and regulatory approval pathways—remain formidable. This review concludes that the rational integration of smart delivery technologies with the genomic and biomarker profiling paradigms of precision medicine holds transformative potential for individualized patient care, and that emerging innovations in artificial intelligence-guided nanoparticle design and multifunctional theranostic platforms will define the next frontier of nanomedicine.

1. Introduction

1.1. Overview of Precision Medicine

Precision medicine—defined as the tailoring of therapeutic strategies to individual patient profiles based on genomic, proteomic, metabolomic, and clinical data—represents a paradigmatic shift from the conventional 'one-size-fits-all' pharmacological model [1, 2]. The identification of biomarkers, oncogenic mutations, and patient-specific disease signatures has enabled the stratification of patient populations and the rational design of targeted therapeutics [3]. Technological advances in next-generation sequencing, liquid biopsies, and multi-omics profiling have substantially expanded the precision medicine toolkit, particularly in oncology, rare genetic disorders, and metabolic diseases [4].

1.2. Role of Smart Drug Delivery Technologies

Smart drug delivery systems (SDDS) are nanotechnology-enabled platforms engineered to release therapeutic payloads in a controlled, site-specific, and stimulus-dependent manner [5, 6]. These systems overcome the fundamental pharmacokinetic and pharmacodynamic limitations of free drugs—including poor aqueous solubility, rapid systemic clearance, non-specific biodistribution, and dose-limiting toxicity—by encapsulating drug molecules within nanostructured vehicles [7]. The ability to program release kinetics in response to pathological stimuli makes SDDS ideally suited to complement the biomarker-guided philosophy of precision medicine [8].

1.3. Need for Targeted and Personalized Therapeutics

The therapeutic efficacy of conventional chemotherapy, antibiotics, and biologics is frequently compromised by off-target effects, systemic toxicity, and the development of resistance mechanisms [9]. Targeted nanocarrier systems capable of recognizing overexpressed tumor antigens, pathogen-specific receptors, or disease-associated enzymatic signatures offer a compelling solution to these challenges [10, 11]. The integration of patient genomic data with nanoparticle design algorithms is expected to further personalize drug delivery by enabling individualized dosing regimens and carrier surface functionalization [12].

1.4. Scope of the Article

This review systematically addresses the major classes of smart nanocarrier platforms (Section 2), delineates the stimuli-responsive and targeting mechanisms that govern precision drug release (Section 3), surveys therapeutic applications across oncology, infectious disease, and genomic medicine (Section 4), and critically evaluates the translational barriers and future directions pertinent to the field (Section 5). The conceptual framework of SDDS in precision medicine is illustrated in Figure 1.

FIGURE 1 — Insert Conceptual Framework Diagram Here
Figure 1. Conceptual framework of smart drug delivery systems in precision medicine. The schematic illustrates the integration of patient-specific biomarker profiling with nanocarrier design, stimuli-responsive release mechanisms, and therapeutic targeting in the context of precision oncology, genomic medicine, and chronic disease management. Nanocarrier types depicted include liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoplatforms, each functionalized with targeting ligands or responsive moieties.

2. Smart Nanocarrier-Based Drug Delivery Systems

A diverse array of nanocarrier architectures has been developed to meet the requirements of precision drug delivery. The major platforms—summarized in Table 1—differ in their physicochemical properties, drug loading capacities, surface functionalization potential, and clinical translation profiles [13].

Table 1: Major smart nanocarrier systems used in precision medicine drug delivery.

Nanocarrier Type	Size Range	Key Feature	Example Application
Polymeric nanoparticles (PLA, PLGA)	100–400 nm	Biodegradable, tunable release	Paclitaxel delivery in breast cancer
Liposomes	50–400 nm	Biocompatible, PEGylatable	Doxorubicin (Doxil®) in oncology
Solid lipid nanoparticles (SLNs)	50–300 nm	Improved stability, low toxicity	Anti-tuberculosis drug delivery
Mesoporous silica nanoparticles (MSNs)	50–300 nm	High drug loading, gated release	siRNA and chemotherapy co-delivery
Dendrimers (PAMAM)	1–10 nm	Multivalent, precise architecture	Gene therapy and cancer targeting
Exosome-based carriers	30–150 nm	Immune evasion, natural targeting	CNS drug delivery and immunotherapy
Carbon nanotubes (CNTs)	1–100 nm	High aspect ratio, surface chemistry	Photodynamic and gene therapy
Quantum dots	2–10 nm	Fluorescent, theranostic potential	Cancer imaging and phototherapy

LCST: Lower Critical Solution Temperature; MSN: Mesoporous Silica Nanoparticle; PAMAM: Polyamidoamine; CNS: Central Nervous System; CNT: Carbon Nanotube.

2.1. Polymeric Nanocarriers

Biodegradable polymeric nanoparticles fabricated from poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and chitosan represent the most extensively investigated class of smart nanocarriers [14]. Their controlled degradation kinetics, tunable surface chemistry, and capacity for co-encapsulation of hydrophilic and hydrophobic agents render them particularly amenable to cancer and gene therapy applications [5]. PLGA nanoparticles encapsulating paclitaxel and siRNA have demonstrated synergistic antitumor activity in preclinical models, and several formulations have advanced to clinical evaluation [13].

2.2. Lipid-Based Nanocarriers

Liposomes are phospholipid bilayer vesicles that have achieved the greatest clinical translation among nanocarrier platforms, exemplified by PEGylated doxorubicin (Doxil®) and liposomal amphotericin B [6, 7]. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) offer enhanced physical stability, scalability, and suitability for oral and parenteral administration of thermosensitive or poorly soluble drugs [15]. Lipid nanoparticles (LNPs) have achieved landmark status through their role in mRNA vaccine delivery, validating the clinical scalability and immunological compatibility of lipid-based SDDS [16].

2.3. Inorganic and Hybrid Nanocarriers

Mesoporous silica nanoparticles (MSNs) possess high surface area, controllable pore dimensions, and versatile gating mechanisms that render them highly effective for stimuli-responsive drug delivery and theranostic applications [8, 17]. Gold nanoparticles (AuNPs) and iron oxide nanoparticles (IONPs) enable photothermal therapy and MRI-guided drug delivery, respectively [18]. Hybrid organic-inorganic nanoplatforms that integrate the biocompatibility of lipid or polymer shells with the imaging and therapeutic functions of inorganic cores are increasingly recognized as superior theranostic vehicles [19].

2.4. Emerging Smart Nanoplatforms

Exosome-based nanocarriers—natural extracellular vesicles of 30–150 nm—confer inherent targeting capabilities, immune evasion properties, and blood-brain barrier permeation potential, positioning them as next-generation

SDDS for central nervous system disorders and immunotherapy [20]. Dendrimers, with their precisely branched architecture and multifunctional surface groups, enable high-density drug conjugation and nucleic acid complexation [10]. Carbon nanotubes and quantum dots have demonstrated utility in photodynamic therapy and multimodal imaging-guided drug delivery, though their long-term safety profiles require further elucidation [21].

3. Stimuli-Responsive and Targeted Drug Release Mechanisms

The therapeutic precision of SDDS is fundamentally governed by their ability to discriminate between healthy and diseased tissue microenvironments. The principal stimuli-responsive mechanisms are categorized in Table 2 and visually summarized in Figure 2.

Table 2: Stimuli-responsive mechanisms used in smart drug delivery systems.

Stimulus Type	Stimulus	Mechanism of Action	Therapeutic Context
Internal	pH	Protonation/deprotonation triggers release	Tumor microenvironment (pH ~6.5)
Internal	Redox (GSH)	Disulfide bond cleavage	Intracellular cancer drug release
Internal	Enzymes	Enzymatic degradation of linker	MMP-responsive cancer therapy
Internal	Hypoxia	Bioreductive activation	Solid tumor targeted therapy
External	Temperature	Phase transition above LCST	Thermosensitive liposomes in tumors
External	Light (NIR/UV)	Photocleavage or photoisomerization	Photodynamic cancer therapy
External	Magnetic field	Magnetothermal actuation	MRI-guided drug delivery
External	Ultrasound	Acoustic cavitation releases payload	Deep-tissue targeted delivery

LCST: Lower Critical Solution Temperature; MMP: Matrix Metalloproteinase; GSH: Glutathione; NIR: Near-Infrared; MRI: Magnetic Resonance Imaging.

3.1. Internal Stimuli-Responsive Systems (pH, Enzymes, Redox)

The acidic tumor microenvironment (pH 6.4–6.8) and endosomal/lysosomal compartments (pH 4.5–5.5) have been extensively exploited to trigger pH-responsive drug release via protonation of amine groups, hydrolysis of acid-labile bonds, or dissolution of pH-sensitive polymeric matrices [11, 22]. Redox-responsive systems exploit the approximately 1,000-fold elevation in intracellular glutathione (GSH) concentration in tumor cells relative to extracellular fluids; disulfide-crosslinked nanocarriers undergo rapid disassembly upon cellular internalization, enabling highly localized drug release [9]. Enzyme-responsive platforms, particularly those sensitive to matrix metalloproteinases (MMPs) and cathepsins overexpressed in malignant tissue, employ protease-cleavable peptide linkers to achieve tumor-selective payload liberation [12].

3.2. External Stimuli-Responsive Systems (Light, Temperature, Magnetic Fields)

Thermosensitive liposomes formulated with phase-transition lipids release their cargo precisely at hyperthermic temperatures (41–43°C), enabling spatially confined drug delivery when combined with focused ultrasound or localized radiofrequency heating [23]. Photo-responsive nanocarriers incorporating azobenzene, spiropyran, or photocleavable ortho-nitrobenzyl groups undergo reversible structural reconfiguration or irreversible bond scission upon irradiation with near-infrared (NIR) or ultraviolet (UV) light, facilitating photodynamic and photothermal combination therapy [18]. Magnetically actuated IONPs permit both MRI-guided tumor visualization and magnetothermal drug release, representing a compelling theranostic paradigm [17, 19].

3.3. Ligand-Mediated Targeting Strategies

Active targeting strategies exploit the overexpression of specific receptors on diseased cell surfaces through the conjugation of ligands—including monoclonal antibodies, aptamers, peptides, folic acid, transferrin, and hyaluronic acid—to nanocarrier surfaces [3, 24]. Antibody-drug conjugates (ADCs) and aptamer-functionalized nanoparticles have demonstrated remarkable tumor selectivity and reduced systemic toxicity in both preclinical and clinical settings [25]. The incorporation of bispecific ligands that simultaneously engage tumor-associated antigens and immune effector cells has opened new avenues for nanocarrier-based cancer immunotherapy [20].

3.4. Controlled and Sustained Release Kinetics

Beyond stimuli-triggered release, many SDDS are designed to sustain therapeutic drug concentrations within the target tissue over extended periods through matrix diffusion, polymer erosion, or osmotic mechanisms [14, 15]. Pharmacokinetic modeling approaches integrating patient-specific clearance rates and receptor expression profiles are increasingly applied to optimize nanocarrier release kinetics for individual patient populations, exemplifying the convergence of computational pharmacology and precision nanomedicine [2, 8].

FIGURE 2 — Insert Stimuli-Responsive Nanocarrier Release Mechanism Diagram Here

Figure 2. Mechanisms of stimuli-responsive and targeted nanocarrier drug release. The schematic depicts the major internal stimuli (pH gradient, glutathione elevation, enzyme overexpression) and external stimuli (near-infrared light, magnetic field, temperature) that trigger cargo release from functionalized nanocarriers. Active targeting via surface-conjugated ligands (antibodies, aptamers, folate) directs nanocarriers to receptor-overexpressing tumor cells, achieving cell-specific drug delivery.

4. Therapeutic Applications in Precision Medicine
4.1. Cancer Therapy and Targeted Chemotherapy

Oncology remains the primary arena for the clinical application of SDDS. Nanocarrier-mediated delivery of chemotherapeutics—including paclitaxel, doxorubicin, cisplatin, and gemcitabine—has been shown to significantly improve tumor drug accumulation via the enhanced permeability and retention (EPR) effect while reducing systemic toxicity [5, 6, 7]. Theranostic nanoplatforms integrating diagnostic imaging with therapeutic payload delivery enable real-time monitoring of treatment response

and adaptive dosing, exemplifying the precision medicine ethos [17, 18, 19]. The combination of targeted nanocarriers with immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies represents a frontier in precision immuno-oncology [25].

4.2. Infectious Diseases and Antimicrobial Therapy
The global threat of antimicrobial resistance (AMR) has stimulated considerable interest in nanocarrier-based delivery of antibiotics, antifungals, and antivirals [22]. Liposomal amphotericin B (AmBisome®) and inhaled tobramycin nanoparticles have demonstrated clinical efficacy against systemic fungal infections and Pseudomonas aeruginosa lung infections, respectively [15, 16]. pH-responsive nanoparticles and enzyme-triggered systems capable of releasing bactericidal payloads selectively within biofilms or intracellular pathogen reservoirs offer promising strategies against multi-drug resistant organisms and intracellular pathogens such as Mycobacterium tuberculosis [9, 11].

4.3. Chronic Diseases and Metabolic Disorders
Smart SDDS are attracting significant attention in the management of chronic diseases including diabetes mellitus, cardiovascular disease, and inflammatory disorders. Glucose-responsive insulin delivery systems employing phenylboronic acid-functionalized nanoparticles or enzymatic glucose oxidase cascades provide closed-loop glycemic control analogous to an artificial pancreas [23, 24]. Nanocarrier-mediated delivery of statins, anti-inflammatory biologics, and oligonucleotide therapeutics to atherosclerotic plaques represents a precision vascular medicine approach [12, 14].

4.4. Personalized Therapeutics and Genomic Medicine
The delivery of nucleic acid therapeutics—including plasmid DNA, messenger RNA, small interfering RNA (siRNA), microRNA, and CRISPR-Cas9 ribonucleoprotein complexes—mandates sophisticated nanocarrier systems capable of endosomal escape, intracellular trafficking, and nuclear targeting [1, 2, 3]. Lipid nanoparticles have emerged as the gold standard for *in vivo* RNA delivery, as validated by the global deployment of COVID-19 mRNA vaccines [16]. Patient-specific neoantigen-based mRNA vaccines encapsulated within ionizable LNPs represent the vanguard of personalized cancer immunotherapy, directly embodying the principles of precision medicine [20, 25].

5. Challenges and Future Perspectives
Despite remarkable preclinical advances, fewer than 50 nanomedicine products have received regulatory approval globally, underscoring the persistent translational gap between laboratory innovation and clinical reality [13, 21]. The primary challenges impeding clinical translation include complex and poorly reproducible manufacturing processes, inadequate understanding of *in vivo* nanoparticle fate, opsonization and mononuclear phagocyte system (MPS) clearance, protein corona formation, and immunotoxicity [4, 8].

Safety and toxicity considerations remain paramount, particularly for inorganic nanocarriers such as quantum dots and carbon nanotubes, which exhibit limited biodegradability and potential for organ accumulation [21]. Long-term biocompatibility data, standardized toxicological assessment protocols, and harmonized international regulatory guidelines for nanomedicine products are urgently needed [24]. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued guidance documents on nanomaterial characterization, but comprehensive regulatory frameworks remain a work in progress [25].

Manufacturing scalability presents a formidable barrier; the physicochemical properties of nanocarriers are highly sensitive to process parameters including mixing conditions, temperature, and shear forces, making large-scale batch-to-batch reproducibility challenging [22, 23]. Microfluidic and continuous-flow manufacturing platforms offer promising solutions for the scalable and reproducible production of nanocarriers with defined size, morphology, and encapsulation efficiency [15].

Future innovations in the field are expected to leverage artificial intelligence (AI) and machine learning algorithms for the *in silico* prediction of nanoparticle-biological interactions, optimization of formulation parameters, and patient stratification for nanocarrier-based therapies [1, 12]. The integration of wearable biosensors and implantable drug delivery devices with stimuli-responsive nanocarrier reservoirs promises closed-loop, feedback-controlled precision therapeutics [10]. Additionally, the exploration of cell-derived nanocarriers—including exosomes and membrane-coated nanoparticles—is anticipated to yield highly biocompatible and target-selective delivery vehicles with natural immune-evasion properties [20].

Table 3: Advantages and limitations of smart drug delivery technologies.

Technology	Advantages	Limitations
Polymeric nanocarriers	Biodegradable, controlled release, scalable	Batch variability, regulatory complexity
Liposomal systems	Biocompatible, established clinical use (Doxil®)	Short shelf-life, aggregation, high cost
Inorganic nanocarriers (MSN, AuNPs)	High drug loading, imaging capability	Potential long-term toxicity, clearance concerns
pH-responsive systems	Tumor-selective, on-demand release	Heterogeneous tumor pH, systemic leakage
Thermosensitive carriers	Spatially controlled release with hyperthermia	Requires external heating device
Ligand-targeted nanocarriers	Enhanced receptor specificity, reduced side effects	Antigen heterogeneity, immune clearance
Exosome-based systems	Immune evasion, natural tropism	Low yield, complex isolation, scalability

6. Conclusion
Smart drug delivery systems represent a transformative and rapidly maturing technological paradigm that is fundamentally reshaping the therapeutic landscape of precision medicine. By enabling spatiotemporally controlled, stimulus-responsive, and receptor-targeted drug delivery, SDDS address the core pharmacological challenges of selectivity, efficacy, and safety that limit conventional therapeutics. The convergence of advanced nanocarrier engineering with genomic medicine, multi-omics biomarker profiling, and computational pharmacology is expected to accelerate the development of truly individualized nanotherapeutic regimens. Realizing this promise will necessitate concerted efforts in safety characterization,

regulatory harmonization, manufacturing scale-up, and rigorous clinical evaluation. With continued interdisciplinary innovation, SDDS are poised to deliver on the transformative promise of precision medicine across oncology, infectious disease, metabolic disorders, and beyond.

References

1. Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: A review of recent success in drug delivery. Clin Transl Med. 2017;6(1):44.
2. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–60.
4. Chow EK, Ho D. Cancer nanomedicine: From drug delivery to imaging. Sci Transl Med. 2013;5(216):216rv4.
5. Gu Z, Biswas A, Zhao M, Tang Y. Tailoring nanocarriers for intracellular protein delivery. Chem Soc Rev. 2011;40(7):3638–55.
6. Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. J Control Release. 2012;160(2):117–34.
7. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–27.
8. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.
9. Cheng R, Meng F, Deng C, Klok HA, Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials. 2013;34(14):3647–57.
10. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971–3010.
11. Gao W, Zhang L. Coating nanoparticles with cell membranes for targeted drug delivery. J Drug Deliv Sci Technol. 2015;29:226–33.
12. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed. 2014;53(46):12320–64.
13. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3):e10143.
14. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 2012;161(2):505–22.
15. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 2012;64:83–101.
16. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.
17. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–34.
18. Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, Rycenga M, et al. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater. 2009;8(12):935–9.
19. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Bhirde A, et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano. 2009;3(2):307–16.
20. Zhang L, Small C, Marcato P. Exosomes as drug delivery vehicles. Nanomedicine. 2021;16(10):891–907.
21. Lacroix LM, Frey Huls N, Ho D, Sun X, Chow E, Sun S. Stable single-crystalline body centered cubic Fe nanoparticles. Nano Lett. 2011;11(4):1641–5.
22. Huh AJ, Kwon YJ. 'Nanoantibiotics': A new paradigm for treating infectious diseases using nanomaterials in the antibiotic-resistant era. J Control Release. 2011;156(2):128–45.
23. Kost J, Langer R. Responsive polymeric delivery systems. Adv Drug Deliv Rev. 2012;64:327–41.
24. Venditto VJ, Szoka FC. Cancer nanomedicines: So many papers and so few drugs! Adv Drug Deliv Rev. 2013;65(1):80–88.
25. Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: An emerging concept in cancer therapy. Angew Chem Int Ed. 2014;53(15):3796–827.

How to Cite This Article

Creative Commons (CC) License